|Table of Contents|
Additional and prolonged anticoagulation in patients with acute coronary syndrome? The ATLAS ACS 2-TIMI 51 trial
The additional application of low-dose rivaroxaban twice daily to standard therapy showed improved efficacy in patients with acute coronary syndrome (ACS) in the ATLAS ACS 2-TIMI 51 (anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome thrombolysis in myocardial infarction) study. All-cause mortality was even reduced with 2 Å~ 2.5 mg rivaroxaban. However, increased efficacy was associated with worse safety with, most importantly, an increased rate of intracranial bleeding.